Anti-Human IGF1R (CD221) (Teprotumumab)

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Teprotumumab. Teprotumumab, also known as RG1507, is a fully human monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF- 1R).

The insulin-like growth factor-1 receptor (IGF1R) is a key receptor tyrosine kinase that regulates cell growth, proliferation, and survival, playing a critical role in cancer development and progression. Overexpression of IGF1R is commonly observed in various cancers, where it promotes tumor growth, transformation, motility, and metastasis. Targeting IGF1R has become a promising therapeutic approach, with strategies including the reduction of receptor expression, inhibition of kinase activity through small-molecule inhibitors, disruption of receptor function using monoclonal antibodies, and neutralization of its ligands. A deeper understanding of the downstream signaling pathways and IGF1R's role in different cancer types is essential for developing more effective treatments^1,2.

Teprotumumab has shown significant potential, particularly in the treatment of thyroid eye disease (TED). Its effectiveness stems from its ability to inhibit IGF1R, which is linked to the thyrotropin receptor, a central factor in TED's pathology. However, teprotumumab therapy is associated with side effects such as hyperglycemia, hearing changes, fatigue, muscle spasms, hair loss, weight loss, gastrointestinal issues, menstrual irregularities, and infusion reactions. Recognizing and managing these adverse effects is crucial for optimizing teprotumumab’s use in clinical practice, ensuring a favorable balance between its risks and benefits^3,4.

IGF1R (Insulin-like Growth Factor 1 Receptor) is primarily found on the surface of human cells and is a transmembrane receptor activated by insulin-like growth factor 1 (IGF-1) and IGF-21. It is widely expressed in various tissues, including the brain, liver, muscle, and bone.

IGF1, IGF2, insulin

1. Park E, Park SY, Kim H, et al. J Pathol Transl Med. 2015;49(5):382-388.
2. Haisa M. J Int Med Res. 2013;41(2):253-264.
3. Yvon C, Khong JJ, Malhotra R, Patel BC. Teprotumumab. In: StatPearls. StatPearls Publishing; 2024. Accessed October 5, 2024. http://www.ncbi.nlm.nih.gov/books/NBK585036/
4. Mn S, Cc K. The Journal of clinical endocrinology and metabolism. 2023;108(9).
5. Teprotumumab Recombinant Monoclonal Antibody (MA5-41915). Accessed October 5, 2024. https://www.thermofisher.com/antibody/product/Teprotumumab-Antibody-Recombinant-Monoclonal/MA5-41915